Pharmacology, Toxicology and Pharmaceutical Science
Atopic Dermatitis
100%
Adverse Event
42%
Upadacitinib
33%
Tralokinumab
33%
Pruritus
21%
Janus Kinase Inhibitor
14%
Dupilumab
11%
Clinical Trial
10%
Acne
10%
Respiratory Tract Infection
10%
Disease Severity
10%
Immunosuppressive Agent
8%
Gastrointestinal Symptom
6%
Nursing and Health Professions
Drug Dose Regimen
33%
Dupilumab
33%
Atopic Dermatitis
33%
Eczema
13%
Disease Course
13%
Disease Severity
6%
Shared Decision-Making
6%
Cohort Analysis
6%
Medicine and Dentistry
Atopic Dermatitis
33%
Targeted Therapy
13%
Janus Kinase Inhibitor
6%
Gastrointestinal Distress
6%
Patient-Reported Outcome
6%
Respiratory Tract Infection
6%
Clinician
6%
Acneiform Eruption
6%
Adverse Event
6%
Clinical Trial
6%
Pruritus
6%
Disease Severity
6%
